Emcure Pharmaceuticals Peer Comparison
NSE: EMCURE | BSE: 544210
₹2,373.00
₹58.60
(2.53%)
As on 13-Nov-2026 09:19IST
Market cap
₹44,057 Cr
Revenue (TTM)
₹10,234 Cr
P/E Ratio
40.3
P/B Ratio
8.2
Div. Yield
0.2 %
Edit
| Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | Concord Biotech | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
44,057 | 26,836 | 17,748 | 13,618 | 12,576 |
Revenue (₹ Cr) |
10,234 | 2,307 | 2,684 | 710 | 1,170 |
Net Profit (₹ Cr) |
1,092.67 | 452.55 | 669.74 | 188.64 | 279.64 |
Net Margin (%) |
10.67 | 19.31 | 24.24 | 25.69 | 22.94 |
RoE (%) |
21.65 | 23.18 | 19.79 | 20.46 | 13.92 |
Price to Earnings |
40.29 | 59.30 | 26.50 | 72.31 | 44.52 |
Price-To-Book |
8.24 | 13.23 | 4.89 | 14.23 | 6.03 |
Income Statement (₹ Cr)
| Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | Concord Biotech | |
|---|---|---|---|---|---|
|
Operating Revenue
|
10,234.10 | 2,307.19 | 2,684.41 | 709.64 | 1,170.41 |
|
Total Income
|
10,245.27 | 2,343.69 | 2,763.43 | 734.34 | 1,218.73 |
|
Total Expenditure
|
8,141.47 | 1,602.28 | 1,761.70 | 458.93 | 766.14 |
|
EBITDA
|
2,092.63 | 704.92 | 922.70 | 250.72 | 404.27 |
|
Depreciation
|
430.12 | 104.34 | 82.27 | 17.12 | 74.77 |
|
EBIT
|
1,662.51 | 600.57 | 840.44 | 233.59 | 329.50 |
|
Interest
|
151.49 | 28.27 | 5.42 | 8.49 | 0.24 |
|
Other Income
|
11.17 | 36.50 | 79.02 | 24.69 | 48.32 |
|
Exceptional Items
|
-27.85 | 0.00 | -25.66 | 0.00 | -3.28 |
|
Profit before Tax
|
1,494.35 | 608.80 | 888.39 | 249.79 | 374.31 |
|
Provision for Tax
|
401.68 | 156.25 | 218.65 | 61.16 | 94.68 |
|
Profit after Tax
|
1,092.67 | 452.55 | 669.74 | 188.64 | 279.64 |
Liabilities (₹ Cr)
| Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | Concord Biotech | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
5,344.04 | 2,029.71 | 3,631.29 | 957.32 | 2,075.76 |
|
Minority Interest
|
0.82 | 0.00 | 0.00 | -0.30 | 3.07 |
|
Non-Current Liabilities
|
980.81 | 381.27 | 146.95 | 106.92 | 53.38 |
|
Current Liabilities
|
3,838.93 | 618.58 | 563.70 | 248.88 | 201.71 |
|
Total Liabilities
|
9,514.48 | 2,930.14 | 4,157.10 | 1,174.38 | 2,231.79 |
Assets (₹ Cr)
| Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | Concord Biotech | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
3,542.74 | 1,471.67 | 1,454.42 | 534.87 | 980.16 |
|
Current Assets
|
6,027.59 | 1,389.85 | 2,864.85 | 723.33 | 1,290.68 |
|
Total Assets
|
9,514.48 | 2,930.14 | 4,157.10 | 1,174.38 | 2,231.79 |
|
Total Debt*
|
1,204.08 | 196.61 | 0.00 | 148.29 | 0.00 |
|
Net Current Assets
|
2,188.66 | 771.28 | 2,301.15 | 474.44 | 1,088.97 |
|
Contingent Liabilities
|
258.92 | 13.18 | 4.82 | -- | 3.76 |
Cashflow (₹ Cr)
| Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | Concord Biotech | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
943.55 | 346.68 | 565.41 | 69.55 | 266.88 |
|
Cash Flow from Investing Activities
|
-1,193.06 | -423.73 | -570.15 | -330.93 | -142.72 |
|
Cash from Financing Activities
|
343.43 | 20.98 | -64.34 | 247.29 | -112.88 |
|
Net Cash Inflow / Outflow
|
93.92 | -56.08 | -69.08 | -14.09 | 11.28 |
Ratios
Profitability Ratios
| Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | Concord Biotech | |
|---|---|---|---|---|---|
|
ROCE (%)
|
25.25 | 27.50 | 24.61 | 28.50 | 18.04 |
|
ROE (%)
|
21.65 | 23.18 | 19.79 | 20.46 | 13.92 |
|
ROA (%)
|
11.17 | 16.27 | 16.78 | 16.29 | 12.86 |
|
EBIT Margin (%)
|
16.24 | 26.03 | 31.31 | 32.92 | 28.15 |
|
Net Margin (%)
|
10.67 | 19.31 | 24.24 | 25.69 | 22.94 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | Concord Biotech | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
21.12 | 50.46 | 8.19 | 26.57 | 4.02 |
|
EBIT Growth (%)
|
32.84 | 138.53 | 24.77 | 26.37 | -11.95 |
|
Net Profit Growth (%)
|
33.33 | 88.45 | 26.27 | 24.97 | -12.44 |
|
EPS Growth (%)
|
38.63 | 131.13 | 29.79 | 8.48 | -12.06 |
|
Book Value Growth (%)
|
11.36 | 22.95 | 18.43 | 79.97 | 11.27 |
Valuation Ratios
| Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | Concord Biotech | |
|---|---|---|---|---|---|
|
Price / Earnings
|
39.53 | 59.30 | 25.70 | 72.31 | 22.07 |
|
Price / Book Value
|
8.24 | 13.23 | 4.89 | 14.23 | 6.03 |
|
Dividend Yield (%)
|
0.16 | 0.16 | 0.35 | 0.12 | 0.63 |
|
EV/EBITDA
|
21.56 | 37.84 | 18.39 | 54.45 | 30.08 |
|
Market Cap (₹ Cr)
|
30,257.56 | 15,412.11 | 11,956.86 | 6,690.53 | 10,627.92 |
Solvency Ratios
| Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | Concord Biotech | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.10 | 0.10 | 0.00 | 0.07 | 0.00 |
|
Short term debt to equity ratio
|
0.16 | -- | -- | 0.12 | -- |
|
Current Ratio
|
1.57 | 2.25 | 5.08 | 2.91 | 6.40 |
|
Quick Ratio
|
0.92 | 1.35 | 3.69 | 1.80 | 4.43 |
|
Interest Coverage
|
10.86 | 22.53 | 165.03 | 30.42 | 1,593.82 |
Operating Efficiency Ratios
| Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | Concord Biotech | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
26.69 | 12.76 | 36.81 | 34.68 | 35.24 |
|
Asset Turnover
|
1.05 | 0.83 | 0.67 | 0.61 | 0.54 |
|
Receivable days
|
88.68 | 77.32 | 144.58 | 115.16 | 169.86 |
|
Inventory Days
|
84.11 | 80.83 | 96.67 | 96.15 | 97.92 |
|
Payable days
|
176.65 | 125.94 | 135.45 | 106.08 | 159.68 |
|
Cash Conversion Cycle
|
-3.86 | 32.22 | 105.80 | 105.23 | 108.11 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
